Shares of Novavax (NASDAQ: NVAX) surged 18.7% on Wednesday after the biotechnology company struck a deal to supply as many as 200 million doses of its coronavirus vaccine candidate to the EU. Should Novavax's vaccine obtain regulatory approval, the European Commission (EC) will purchase up to 100 million doses. Novavax hopes to complete the rolling submission for its drug to the European Medicines Agency in the third quarter.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting